1. Home
  2. CWK vs MTSR Comparison

CWK vs MTSR Comparison

Compare CWK & MTSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CWK
  • MTSR
  • Stock Information
  • Founded
  • CWK 1784
  • MTSR 2022
  • Country
  • CWK United States
  • MTSR United States
  • Employees
  • CWK N/A
  • MTSR N/A
  • Industry
  • CWK Real Estate
  • MTSR
  • Sector
  • CWK Finance
  • MTSR
  • Exchange
  • CWK Nasdaq
  • MTSR NYSE
  • Market Cap
  • CWK 2.7B
  • MTSR 3.0B
  • IPO Year
  • CWK 2018
  • MTSR 2025
  • Fundamental
  • Price
  • CWK $11.71
  • MTSR $39.47
  • Analyst Decision
  • CWK Hold
  • MTSR Strong Buy
  • Analyst Count
  • CWK 7
  • MTSR 6
  • Target Price
  • CWK $13.43
  • MTSR $55.25
  • AVG Volume (30 Days)
  • CWK 2.0M
  • MTSR 843.0K
  • Earning Date
  • CWK 07-28-2025
  • MTSR 08-26-2025
  • Dividend Yield
  • CWK N/A
  • MTSR N/A
  • EPS Growth
  • CWK 1337.16
  • MTSR N/A
  • EPS
  • CWK 0.69
  • MTSR N/A
  • Revenue
  • CWK $9,546,300,000.00
  • MTSR N/A
  • Revenue This Year
  • CWK $5.77
  • MTSR N/A
  • Revenue Next Year
  • CWK $5.65
  • MTSR N/A
  • P/E Ratio
  • CWK $17.00
  • MTSR N/A
  • Revenue Growth
  • CWK 1.24
  • MTSR N/A
  • 52 Week Low
  • CWK $7.64
  • MTSR $12.30
  • 52 Week High
  • CWK $16.11
  • MTSR $40.24
  • Technical
  • Relative Strength Index (RSI)
  • CWK 63.15
  • MTSR N/A
  • Support Level
  • CWK $11.26
  • MTSR N/A
  • Resistance Level
  • CWK $11.90
  • MTSR N/A
  • Average True Range (ATR)
  • CWK 0.37
  • MTSR 0.00
  • MACD
  • CWK 0.04
  • MTSR 0.00
  • Stochastic Oscillator
  • CWK 87.25
  • MTSR 0.00

About CWK Cushman & Wakefield plc

Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.

About MTSR METSERA INC

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Share on Social Networks: